Dr Reddy’s Laboratories and its subsidiary, Promius Pharma today announced filing of three new drug applications (NDAs) with the US Food and Drug Administration.
Of the three, two are related to dermatology (skincare) applications and one is a corticosteroid, the company said in a filing to the BSE today.
Raghav Chari, Executive Vice President of Proprietary Products at Dr Reddy’s and President of Primus Pharma said “These products represent new, compelling options for segments of patients suffering from Psoriasis, Rosacea and Migraine”.
They are also the first of a large basket of products targeting conditions predominantly treated by dermatologist and neurologists. Upon approval, the products will be commercialised by Promius Pharma.
By Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru Insomnia, the persistent inability…
Illuminating Latest Advances in Migraine Diagnosis and Treatment New Delhi, December 21, 2024: In a…
New Delhi, December 20, 2024: The healthcare sector is undergoing a transformation fueled by technological…
National, December 20, 2024: DKMS just published its first Global Impact Report that outlines the organization's…
Ahmedabad, December 19, 2024: Sterling Biotech Limited, a joint venture between Perfect Day and Zydus, has…
New Delhi, December 19, 2024: Antara Senior Care, an integrated eco-system provider for lifestyle and…